No Data
No Data
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
TD Cowen analyst Ritu Baral maintains $Amicus Therapeutics(FOLD.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 47.6% and
Amicus Therapeutics(FOLD.US) Officer Sells US$61,029.28 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 6,100 shares of common stock on Jul 5, 2024 at an average price of $10.0048 for a total value of $61,029.28.Source: Announcement What
Stifel Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Stifel analyst Dae Gon Ha maintains $Amicus Therapeutics(FOLD.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 37.5% and a
Amicus Therapeutics(FOLD.US) Officer Sells US$14,002.94 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 1,400 shares of common stock on Jul 1, 2024 at an average price of $10.0021 for a total value of $14,002.94.Source: Announcement What is
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Investors in Amicus Therapeutics (NASDAQ:FOLD) From a Year Ago Are Still Down 19%, Even After 3.9% Gain This Past Week